Amgen's bone drug gets delayed by the FDA, and Wall Street isn't surprised
Posted on October 19, 2009 at 12:20 PM EDT
DailyFinance : Drugmaker Amgen (AMGN) did not win the Food and Drug Administration's approval on Monday for its experimental osteoporosis treatment denosumab. Amgen, based in Thousand Oaks, California, had been banking on the drug's approval for company growth, but ... Read more